Barry Jones, Ph.D.
Director, LCMS Biologics and Biomarkers
Dr. Barry Jones joined Advion Biosciences in 2007 and began the LCMS Biologics Group in 2008. Barry now leads the large molecule LC-MS method development group at Q2 Solutions. Research within the LC-MS biologics group at Q2 Solutions is focused on targeted quantitative LC-MS/MS analysis of endogenous biomolecules and large molecule biotherapeutics on triple quadrupole and orbitrap instruments. Dr. Jones is particularly interested in the application of hybrid Immunoaffinity-LC-MS/MS methods to high-throughput bioanalysis, as well as the scientific challenges and regulatory strategies for validation of LC-MS biomarker assays supporting drug development in a regulated environment.

Prior to joining Q2 Solutions, Dr. Jones led the Mass Spectrometry Facility at Binghamton University, N.Y. using Q-TOF and MALDI mass spectrometry and nanoESI techniques in support of proteomic research. He earned his Ph.D. in Physical Chemistry at Binghamton University in 2006.